Hamburg, Germany – April 10, 2025 – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO), a prominent life science company, has announced the upcoming release of its financial results for the year 2024. The announcement is scheduled for Thursday, April 17, 2025.

In conjunction with the financial results, Evotec will host a conference call to discuss the 2024 performance and provide an update on the findings of its recently completed strategic review. The conference call, conducted in English, is slated for 2.00 pm CEST (1.00 pm BST, 8.00 am ET) on April 17, 2025.

Interested parties have the option to participate via audio webcast or phone. Registration for the audio webcast, including access to presentation slides, is available through a dedicated registration link. For those preferring to join by phone, pre-registration is required to receive specific dial-in details, including a telephone number, access code, and PIN. A simultaneous slide presentation will also be available for phone participants through a separate link. An on-demand version of the webcast will be accessible on Evotec’s official website following the live event.

Evotec SE operates with a unique business model focused on discovering and developing effective therapeutics. The company leverages a combination of innovative technologies, data, and scientific expertise to develop pharmaceutical products. Evotec engages in high-value pipeline co-creating partnerships and offers solutions to top-tier pharmaceutical companies, biotechnology firms, academic institutions, and other healthcare stakeholders.

The company’s strategic activities span a range of therapeutic areas, including neurology, oncology, metabolic diseases, and infectious diseases. Evotec aims to establish a world-leading co-owned pipeline for innovative therapeutics, currently managing a portfolio of over 100 proprietary and co-owned R&D projects, from early discovery to clinical development.

With a global presence, Evotec employs over 4,800 individuals across its sites in Europe and the USA. These locations provide synergistic technologies and services, operating as complementary clusters of excellence.

Further information about Evotec SE can be found on their website (www.evotec.com) and social media channels, including X/Twitter (@Evotec) and LinkedIn.

Forward-Looking Statements

The announcement contains forward-looking statements regarding future events, including the proposed offering and listing of Evotec’s securities. Terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would,” and similar expressions identify these statements. These forward-looking statements are based on available information and reasonable assumptions made by Evotec at the time of the announcement. However, there is no guarantee that these expectations will be accurate, as they involve known and unknown risks, uncertainties, and contingencies beyond Evotec’s control.

Evotec expressly disclaims any obligation to publicly update or revise any forward-looking statements to reflect changes in expectations, events, conditions, or circumstances on which the statements are based.

Contact Information

For further information, please contact:

Volker Braun
EVP Head of Global Investor Relations & ESG
[email protected]